Sign Up Today and Learn More About Precision Neuroscience Stock
Invest in or calculate the value of your shares in Precision Neuroscience or other pre-IPO companies through EquityZen's platform.
Precision Neuroscience Stock (PRNE)
Precision Neuroscience is a neural platform that engages in brain-computer interface technology.
About Precision Neuroscience Stock
Founded
2021
Headquarters
New York, NY, US
Industries
Software, Artificial Intelligence, Data and Analytics
Precision Neuroscience Press Mentions
Stay in the know about the latest news on Precision Neuroscience
Founder of Neuralink rival Precision Neuroscience reveals what people often get wrong about brain-implant surgery
businessinsider • Jun 27, 2025
Precision Neuroscience Named to Fast Company’s World Changing Ideas and Inc.’s Best Workplaces Lists
morningstar • Jun 18, 2025
Precision Neuroscience Named to Fast Company’s World Changing Ideas and Inc.’s Best Workplaces Lists
globenewswire • Jun 18, 2025
Precision Neuroscience Expands Leadership Team With Key Hires From Meta and FDA
biospace • Jun 12, 2025
Precision Neuroscience Expands Leadership Team With Key Hires From Meta and FDA
globenewswire • Jun 12, 2025
Precision Neuroscience Management
Leadership team at Precision Neuroscience
Co-Founder & CEO
Michael Mager
Co-Founder & CSO
Benjamin Rapoport
Join now and verify your accreditation status to gain access to:
- Precision Neuroscience Current Valuation
- Precision Neuroscience Stock Price
- Precision Neuroscience Management
- Available deals in Precision Neuroscience and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Precision Neuroscience Cap Table and Funding History by Share Class and Liquidity Preferences
- Precision Neuroscience Revenue and Financials
- Precision Neuroscience Highlights
- Precision Neuroscience Business Model
- Precision Neuroscience Risk Factors
- Precision Neuroscience Research Report from SACRA Research
Trading Precision Neuroscience Stock
How to invest in Precision Neuroscience stock?
Accredited investors can buy pre-IPO stock in companies like Precision Neuroscience through EquityZen funds. These investments are made available by existing Precision Neuroscience shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Precision Neuroscience stock?
Shareholders can sell their Precision Neuroscience stock through EquityZen's private company marketplace. EquityZen's network includes over 380K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 47K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
